Cullinan Therapeutics 향후 성장

Future 기준 점검 2/6

Cullinan Therapeutics 의 수익은 연간 1% 감소할 것으로 예상되는 반면, 연간 수익은 46.1% 로 증가할 것으로 예상됩니다. EPS는 연간 10.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -27.2% 로 예상됩니다.

핵심 정보

-1.0%

이익 성장률

10.22%

EPS 성장률

Biotechs 이익 성장	23.1%
매출 성장률	46.1%
향후 자기자본이익률	-27.18%
애널리스트 커버리지	Good
마지막 업데이트	17 Dec 2025

최근 향후 성장 업데이트

Recent updates

Cullinan Therapeutics: Worthy Of A Small Position

Oct 17

Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Situation

Oct 10

Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Situation

Jun 21

Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data

Apr 08

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Feb 27

Cullinan Therapeutics: Casting A Wide Net With Their Pipeline

Jan 08

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Nov 20

Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease

Aug 30

Checking Into Cullinan Therapeutics

Jun 09

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Apr 23

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Jun 24

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Mar 05

이익 및 매출 성장 예측

NasdaqGS:CGEM - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	21	-256	-211	-210	4
12/31/2027	41	-192	-201	-200	7
12/31/2026	25	-192	-191	-190	10
12/31/2025	7	-214	-177	-176	9
9/30/2025	N/A	-217	-174	-174	N/A
6/30/2025	N/A	-207	-172	-172	N/A
3/31/2025	N/A	-179	-150	-150	N/A
12/31/2024	N/A	-167	-145	-145	N/A
9/30/2024	N/A	-144	-127	-127	N/A
6/30/2024	N/A	-142	-127	-127	N/A
3/31/2024	N/A	-132	-122	-122	N/A
12/31/2023	N/A	-153	-134	-134	N/A
9/30/2023	N/A	-156	-142	-141	N/A
6/30/2023	N/A	-142	-163	-161	N/A
3/31/2023	N/A	65	-157	-156	N/A
12/31/2022	N/A	111	-128	-127	N/A
9/30/2022	N/A	105	-117	-117	N/A
6/30/2022	N/A	113	-73	-73	N/A
3/31/2022	N/A	-78	-64	-64	N/A
12/31/2021	19	-66	-43	-43	N/A
9/30/2021	19	-61	-38	-38	N/A
6/30/2021	19	-54	-36	-36	N/A
3/31/2021	19	-47	-26	-26	N/A
12/31/2020	N/A	-52	-30	-30	N/A
9/30/2020	N/A	-28	-25	-25	N/A
6/30/2020	N/A	-25	-22	-22	N/A
3/31/2020	N/A	-21	-21	-21	N/A
12/31/2019	N/A	-21	-21	-21	N/A

애널리스트 향후 성장 전망

수입 대 저축률: CGEM 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: CGEM 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: CGEM 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: CGEM 의 수익(연간 46.1%)이 US 시장(연간 10.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: CGEM 의 수익(연간 46.1%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: CGEM는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/31 09:16
종가	2025/12/31 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Cullinan Therapeutics, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Julian Harrison	BTIG
Thomas Shrader	BTIG
Kaveri Pohlman	BTIG

Cullinan Therapeutics 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Price target increased by 11% to US$28.78

Price target decreased by 12% to US$28.25

Consensus revenue estimates fall by 52%

Consensus EPS estimates upgraded to US$3.01 loss

Consensus revenue estimates increase by 19%

Price target increased by 13% to US$28.71

Recent updates

President recently sold US$99k worth of stock

Price target increased by 11% to US$28.78

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation At the 67Th Ash Meeting

Cullinan Therapeutics, Inc. Receives Fda Fast Track Designation for Cln-049, A Novel Flt3xcd3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Cullinan Therapeutics, Inc. to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting

Cullinan Therapeutics, Inc. Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

Cullinan Therapeutics: Worthy Of A Small Position

Taiho Oncology and Cullinan Therapeutics Announces to Present Data on Zipalertinib in Patients with Nsclc with Egfr Mutations and Active Brain Metastases At the Esmo Congress 2025

Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Situation

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer

Cullinan Therapeutics, Inc. Announces Board Changes, Effective August 7, 2025

Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) dropped from Russell 3000E Growth Index

Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Situation

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology

Cullinan Therapeutics, Inc., Taiho Pharmaceutical Co., Ltd., and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

Price target decreased by 12% to US$28.25

Cullinan Therapeutics, Inc. to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjogren's Disease in the United States

Cullinan Therapeutics, Inc., Annual General Meeting, Jun 12, 2025

Cullinan Therapeutics, Inc. to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Cullinan Therapeutics, Inc. Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978

Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data

Consensus revenue estimates fall by 52%

President recently sold US$107k worth of stock

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

New major risk - Shareholder dilution

Cullinan Therapeutics: Casting A Wide Net With Their Pipeline

President recently sold US$100k worth of stock

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Cullinan Therapeutics, Inc. Announces Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, to Be Presented at ACR Convergence 2024

Cullinan Therapeutics, Inc. to Present Preclinical Data for CLN-978, a CD19-Directed T Cell Engager, at ACR Convergence 2024

Cullinan Therapeutics, Inc Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Cullinan Therapeutics, Inc. Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Chief Scientific Officer notifies of intention to sell stock

Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease

Independent Director exercised options to buy US$402k worth of stock.

Checking Into Cullinan Therapeutics

Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib

Independent Director exercised options to buy US$2.4m worth of stock.

Consensus EPS estimates upgraded to US$3.01 loss

Cullinan Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Cullinan Therapeutics, Inc. Announces Board Changes

Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates increase by 19%

Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Price target increased by 13% to US$28.71

Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in funding

Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024

Chief Business Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Cullinan Oncology, Inc. to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Price target decreased by 11% to US$25.25

New minor risk - Profitability

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. Announces the Launch of the REZILIENT3 Trial

Investor sentiment improves as stock rises 17%

High number of new and inexperienced directors

Chief Development Officer notifies of intention to sell stock

Investor sentiment improves as stock rises 16%

Cullinan Oncology, Inc. Announces First Clinical Data from its Phase 1 Study of CLN-619 in Patients with Advanced Solid Tumors

Cullinan Oncology, Inc. Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, Novel T-Cell Engager for Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Investor sentiment deteriorated over the past week

Chief Development Officer notifies of intention to sell stock

Price target decreased to US$34.00

Cullinan Oncology Appoints of David P. Ryan to Its Board of Directors